Global Retirement Partners LLC Boosts Stock Holdings in Pfizer Inc. $PFE

Global Retirement Partners LLC grew its position in Pfizer Inc. (NYSE:PFE) by 60.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 216,502 shares of the biopharmaceutical company’s stock after acquiring an additional 81,713 shares during the quarter. Global Retirement Partners LLC’s holdings in Pfizer were worth $5,391,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in PFE. Brighton Jones LLC boosted its stake in shares of Pfizer by 1,282.4% in the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after acquiring an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC boosted its stake in shares of Pfizer by 12.5% in the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after acquiring an additional 2,087 shares during the last quarter. United Bank boosted its stake in shares of Pfizer by 12.4% in the second quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock worth $1,408,000 after acquiring an additional 6,415 shares during the last quarter. Sei Investments Co. boosted its stake in shares of Pfizer by 31.5% in the second quarter. Sei Investments Co. now owns 2,635,691 shares of the biopharmaceutical company’s stock worth $63,889,000 after acquiring an additional 631,523 shares during the last quarter. Finally, HUB Investment Partners LLC boosted its stake in shares of Pfizer by 45.3% in the second quarter. HUB Investment Partners LLC now owns 102,327 shares of the biopharmaceutical company’s stock worth $2,480,000 after acquiring an additional 31,896 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on PFE. Wolfe Research restated an “underperform” rating and issued a $26.00 price target on shares of Pfizer in a research report on Thursday, May 14th. Argus upgraded Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price target for the company in a research report on Monday, March 2nd. Daiwa Securities Group lowered Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price target for the company. in a research report on Thursday, February 12th. HSBC upped their price target on Pfizer from $29.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, March 17th. Finally, Cantor Fitzgerald restated a “neutral” rating and issued a $27.00 price target on shares of Pfizer in a research report on Wednesday, February 4th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, twelve have issued a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $28.61.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer announced strong Phase 2 results for its investigational 25-valent pneumococcal vaccine in infants, including a stronger immune response than Prevnar 20 and up to 15-fold higher antibody levels against a key strain. The company is now moving the program into pivotal Phase 3 testing, which could support future vaccine growth. Article Title
• Positive Sentiment: The company also received a broader European indication for HYMPAVZI, adding another recent R&D win that may strengthen Pfizer’s hemophilia franchise and improve investor confidence in the pipeline. Article Title
• Positive Sentiment: Pfizer and Rigel Pharmaceuticals expanded a commercialization deal for VEPPANU (vepdegestrant), creating another potential partnership-driven revenue stream tied to oncology. Article Title
• Positive Sentiment: Pfizer’s oncology growth story is also getting attention, with coverage pointing to Padcev, biosimilars, and late-stage pipeline assets as key long-term drivers. Article Title
• Neutral Sentiment: Pfizer was also listed as a participant in an AI industry summit, but this appears unrelated to the company’s core investment thesis and is unlikely to move the stock on its own. Article Title

Pfizer Price Performance

PFE stock opened at $25.93 on Friday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94. The business has a 50 day simple moving average of $26.88 and a 200-day simple moving average of $26.23. The firm has a market capitalization of $147.76 billion, a PE ratio of 19.79 and a beta of 0.35. Pfizer Inc. has a 1 year low of $22.81 and a 1 year high of $28.75.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The firm had revenue of $14.45 billion for the quarter, compared to analysts’ expectations of $13.84 billion. During the same period in the prior year, the firm posted $0.92 earnings per share. The firm’s quarterly revenue was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities research analysts anticipate that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be issued a $0.43 dividend. The ex-dividend date is Friday, May 8th. This represents a $1.72 dividend on an annualized basis and a yield of 6.6%. Pfizer’s dividend payout ratio is currently 131.30%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.